|
DE19814084B4
(de)
*
|
1998-03-30 |
2005-12-22 |
Lts Lohmann Therapie-Systeme Ag |
D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
|
|
US6562370B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
|
|
US6582724B2
(en)
|
1999-12-16 |
2003-06-24 |
Dermatrends, Inc. |
Dual enhancer composition for topical and transdermal drug delivery
|
|
US6673363B2
(en)
|
1999-12-16 |
2004-01-06 |
Dermatrends, Inc. |
Transdermal and topical administration of local anesthetic agents using basic enhancers
|
|
US6645520B2
(en)
|
1999-12-16 |
2003-11-11 |
Dermatrends, Inc. |
Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
|
|
US6586000B2
(en)
|
1999-12-16 |
2003-07-01 |
Dermatrends, Inc. |
Hydroxide-releasing agents as skin permeation enhancers
|
|
US6565879B1
(en)
|
1999-12-16 |
2003-05-20 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
|
|
US6562368B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
|
|
US6558695B2
(en)
|
1999-12-16 |
2003-05-06 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
|
|
US6562369B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
|
|
DE10041479A1
(de)
*
|
2000-08-24 |
2002-03-14 |
Sanol Arznei Schwarz Gmbh |
Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
|
|
DE10053397A1
(de)
|
2000-10-20 |
2002-05-02 |
Schering Ag |
Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
|
|
DE10043321B4
(de)
*
|
2000-08-24 |
2005-07-28 |
Neurobiotec Gmbh |
Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
|
|
DE10064453A1
(de)
*
|
2000-12-16 |
2002-07-04 |
Schering Ag |
Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
|
|
DE10103860B4
(de)
*
|
2001-01-30 |
2004-12-23 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
|
|
US8211462B2
(en)
*
|
2002-07-30 |
2012-07-03 |
Ucb Pharma Gmbh |
Hot-melt TTS for administering rotigotine
|
|
US8246980B2
(en)
|
2002-07-30 |
2012-08-21 |
Ucb Pharma Gmbh |
Transdermal delivery system
|
|
DE10234673B4
(de)
|
2002-07-30 |
2007-08-16 |
Schwarz Pharma Ag |
Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
|
|
EP1386605A1
(en)
*
|
2002-07-30 |
2004-02-04 |
Schwarz Pharma Ag |
Improved transdermal delivery system for the administration of rotigotine
|
|
EP1386604A1
(en)
*
|
2002-07-30 |
2004-02-04 |
Schwarz Pharma Ag |
Improved transdermal delivery system
|
|
US8246979B2
(en)
|
2002-07-30 |
2012-08-21 |
Ucb Pharma Gmbh |
Transdermal delivery system for the administration of rotigotine
|
|
PT1426049E
(pt)
*
|
2002-12-02 |
2005-09-30 |
Sanol Arznei Schwarz Gmbh |
Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
|
|
DE10261696A1
(de)
*
|
2002-12-30 |
2004-07-15 |
Schwarz Pharma Ag |
Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
|
|
US20040214215A1
(en)
*
|
2003-03-07 |
2004-10-28 |
Yu Ruey J. |
Bioavailability and improved delivery of alkaline pharmaceutical drugs
|
|
US20050196418A1
(en)
*
|
2004-03-04 |
2005-09-08 |
Yu Ruey J. |
Bioavailability and improved delivery of alkaline pharmaceutical drugs
|
|
EP2215072B1
(en)
|
2007-11-28 |
2015-09-02 |
UCB Pharma GmbH |
Polymorphic form of rotigotine
|
|
JP5485135B2
(ja)
|
2008-02-27 |
2014-05-07 |
久光製薬株式会社 |
貼付製剤
|
|
WO2009107478A1
(ja)
*
|
2008-02-27 |
2009-09-03 |
久光製薬株式会社 |
貼付剤及び包装体
|
|
DE102008013701A1
(de)
*
|
2008-03-11 |
2009-09-17 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales Therapeutisches System mit stabilisierter Membran
|
|
JP5664871B2
(ja)
*
|
2009-06-19 |
2015-02-04 |
株式会社 メドレックス |
アリピプラゾールと有機酸を有効成分とする外用剤組成物
|
|
DE102010024105A1
(de)
*
|
2010-06-17 |
2011-12-22 |
Grünenthal GmbH |
Transdermale Verabreichung von Memantin
|
|
US11123305B2
(en)
|
2012-07-26 |
2021-09-21 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch
|
|
CN104487072B
(zh)
*
|
2012-07-26 |
2017-08-04 |
久光制药株式会社 |
贴附剂及其制造方法
|
|
CN110087640A
(zh)
|
2016-12-20 |
2019-08-02 |
罗曼治疗系统股份公司 |
包含阿塞那平的透皮治疗系统
|
|
KR102614709B1
(ko)
|
2016-12-20 |
2023-12-18 |
에르테에스 로만 테라피-시스테메 아게 |
아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
|
|
US11033512B2
(en)
|
2017-06-26 |
2021-06-15 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
|
|
KR20210022656A
(ko)
|
2018-06-20 |
2021-03-03 |
에르테에스 로만 테라피-시스테메 아게 |
아세나핀을 함유하는 경피 치료 시스템
|
|
AU2020240797A1
(en)
*
|
2019-03-19 |
2021-10-21 |
Nobelpharma Co., Ltd. |
Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability
|
|
DE102020207642A1
(de)
*
|
2020-06-19 |
2021-12-23 |
Lts Lohmann Therapie-Systeme Ag |
Verfahren zur herstellung von asenapin in form seiner freien base
|
